Enovis Corp Stock Price, News & Analysis

Enovis Corporation (NYSE: ENOV) announced its financial results for Q4 and the fiscal year ended December 31, 2022. Q4 net sales reached $409 million, marking a 2% increase, driven by 5% organic growth, despite a 3% currency headwind. The Reconstructive segment reported a 12% growth, while the Prevention and Recovery segment declined by 2%. The fiscal year saw net sales of $1.6 billion, with a 10% increase.

However, the company faced a Q4 operating loss of $28 million and a net loss from continuing operations of $55 million. For 2023, Enovis expects revenue growth of 5-6%, with adjusted earnings per diluted share projected between $2.15 and $2.30.

Enovis Corporation (NYSE: ENOV), a medical technology growth company, has announced an investor conference call and live webcast to discuss its Q4 and full year 2022 financial results. This event is scheduled for February 23, 2023, at 8:30 AM ET, with an earnings press release set to be issued earlier that same morning. Investors can access the webcast through the Enovis website, and a replay will also be available later. Enovis is committed to developing innovative solutions that improve patient outcomes, focusing on orthopedics and related sectors.

Enovis Corporation (NYSE: ENOV) is set to showcase its innovative Foot & Ankle products at the 2023 ACFAS Scientific Conference in Los Angeles from February 9-12, 2023. This year, Enovis will present a variety of offerings, including DynaNail Helix™, DynaClip Delta™, and Arsenal Ankle Plating System™, centered around improving patient outcomes. The company aims to enhance efficiency with its unique solutions. Enovis will also host a sponsored session focusing on product innovation on February 10, where attendees can engage with hands-on demonstrations.

Enovis Corporation (NYSE: ENOV) has launched the DynaClip Delta™ and DynaClip Quattro™ bone staples, expanding its foot and ankle product line. These innovative staples enhance procedural efficiency for surgeons and deliver sustained dynamic compression for mid-foot and first metatarsophalangeal joint fusions. The DynaClip Delta staples are noted for their stiffness, rivaling traditional constructs, while the Quattro version features a four-legged design for improved surgical versatility. Enovis aims to provide cutting-edge solutions that enhance patient outcomes and disrupt the market.

Enovis Corporation (NYSE: ENOV) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, scheduled for January 9, 2023, at 3:00 p.m. PST (6:00 p.m. EST). The event will be accessible via a live audio webcast, with replays available on the company's website. Enovis focuses on developing medical technology solutions that enhance patient outcomes and streamline workflows, driving active lifestyles in orthopedics and beyond.

Enovis Corporation announced the FDA's approval of the STAR Patient Specific Instrumentation (STAR PSI System) for total ankle replacements, marking a significant advancement for surgeons and patients. This system allows for personalized pre-operative planning, integrating a 3D visualization of each patient's ankle joint, which enhances surgical accuracy and efficiency. The STAR PSI System is set to enter Early Product Surveillance in December 2022, with a full launch anticipated by March 2023. This product joins Enovis' expanding portfolio aimed at improving patient outcomes.

Enovis Corporation (NYSE: ENOV) has launched the DynaNail Helix™, enhancing dynamic compression in foot and ankle fusion procedures. This innovative product leverages proven NiTiNOL technology to provide sustained compression, which traditional screws lack. The DynaNail Helix is designed for easy insertion, minimizes the need for manual adjustment, and allows up to 4mm of post-operative compression to adapt to bone resorption. As part of Enovis' comprehensive suite, it aims to improve patient recovery and outcomes, reinforcing the company's commitment to advanced medical technologies.

Enovis Corporation (NYSE: ENOV) has been awarded the Industry Innovation Award at the American Academy of Hip and Knee Surgeons (AAHKS) Annual Meeting for its ARVIS Augmented Reality Surgical Guidance System. This groundbreaking AR technology allows orthopedic surgeons to visualize precision guidance during hip and knee surgeries. Unlike large robotic systems, ARVIS is FDA-cleared and designed for easy adoption in surgical centers, providing more patients access to advanced surgical options. Enovis aims to enhance patient outcomes with ongoing innovations.

Enovis Corporation (NYSE: ENOV) reported third-quarter 2022 sales of $384 million, a 7% increase year-over-year, driven by double-digit growth in its Reconstructive segment. However, the company faced a net loss of $(66) million or $(1.22) per diluted share. Adjusted earnings per share improved by 34% to $0.59, with adjusted EBITDA at $57 million, representing 14.9% of sales. Enovis launched innovative products, including the EMPOWR 3D Knee™ and connected bracing solutions. The company anticipates total sales growth of approximately 10% for 2022.